DOCSLIB.ORG

Enhanced Reference List of Cochrane Review Protocols

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enhanced Reference List of Cochrane Review Protocols Enhanced Reference List of Cochrane Review Protocols Selected by the Cochrane Neurological Network Published in the Cochrane Library (CL) through Issue 3, 2006 This database of COCHRANE REVIEW PROTOCOLS contains titles - in alphabetical order - of protocols – of neurological interest – published in the Cochrane Library through Issue 3, 2006. They were selected and compiled by the Cochrane Neurological Network. The standard path for registering a systematic review is the registration of the title, the submission of the protocol and, finally, the completed review. These protocols are divided by disease category according to the Index of Diseases created and maintained by the Cochrane Neurological Network. See the Index of Diseases - in alphabetical order - with the corresponding number of protocols that can be found in this list. (Last update: 26 September 2006) Index of Diseases ACQUIRED METABOLIC DISORDERS ( 1 ) MIGRAINE AND HEADACHE ( 13 ) ALCOHOL AND ALCOHOLISM ( 2 ) MOTOR NEURON DISEASES ( 7 ) BACK ( 11 ) MOVEMENT DISORDERS ( 14 ) BRAIN AND SPINAL CORD TUMORS ( 5 ) NEUROLOGICAL SERVICES ( 1 ) BRAIN AND SPINAL INJURIES ( 16 ) NEUROMUSCULAR DISORDERS ( 9 ) CEREBROVASCULAR DISEASE - ACUTE TREATMENT ( 14 ) NEUROSURGERY ( 1 ) CEREBROVASCULAR DISEASE - PREVENTION ( 20 ) NUTRITIONAL DEFICIENCY DISORDERS ( 0 ) CEREBROVASCULAR DISEASE-Rehabilitation/Post Acute ( 12 ) PAIN ( 11 ) CSN AND SPINAL INFECTIONS ( 5 ) PERIPHERAL AND CRANIAL NERVES NEUROPATHIES ( 21 ) DEMENTIA ( 24 ) RARE AND HEREDITARY DISEASES ( 2 ) DEMYELINATING DISEASES ( 13 ) SLEEP DISORDERS ( 8 ) EPILEPSY ( 10 ) SUBARACHNOID HAEMORRHAGE ( 0 ) INTENSIVE CARE AND PALLIATIVE CARE ( 3 ) SYMPTOMATIC TREATMENT ( 36 ) INTOXICATIONS AND POISONINGS ( 0 ) OTHERS ( 8 ) ACQUIRED METABOLIC DISORDERS Magnesium sulfate for term infants following perinatal asphyxia Kent A, Kecskes Z; Neonatal Group In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd. ALCOHOL and ALCOHOLISM Pharmacotherapy for preventing and treating alcohol withdrawal seizures Leone MA, Brathen G, Chick J, Faggiano F, Hillbom M, McIntosh C; Epilpesy Group In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd. Selective serotonin inhibitors for the treatment of alcohol use disorders Shand FS; Drugs and Alcohol Group In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd. BACK Antidepressants for non-specific low-back pain Van Tulder MW, Hienkens EEM, Roland M, Assendelft WJJ; Back Group In: The Cochrane Library, Issue 4, 2001. Oxford: Update Software Chiropractic interventions for low-back pain French SD, Grant WD , Green S , Walker B; Back Group In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd. Insoles for prevention and treatment of back pain Sahar T, Lev I, Odebiyi DO, Kandel L, Ne'eman V, Brezis M, Lahad A; Back Group In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd. Interventions for preventing hypotension in adults receiving spinal anaesthesia Delgado MB, Alvarez Torres H, Bonilla A, Rodriguez N; Anaesthesia Group In: The Cochrane Library, Issue 4, 2004. Chichester, UK: John Wiley & Sons, Ltd. Low level laser therapy for nonspecific low-back pain Yousefi NR, Schonstein E, Rashidian A, Heidari K, Shakiba B, Mortaz HSA, Akbari KM, Mortaz HSO, Irani S, Jonaidi A, Enzevaie A; Back Group In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley & Sons, Ltd. Manual Material Handling Advice and Assistive Devices for Preventing and Treating Back Pain in Workers Martimo KP , Verbeek J , Karppinen J , Furlan A D , Kuijer PPFM , Viikari-Juntura E , Takala EP, Jauhiainen M; Back Group In: The Cochrane Library, Issue 2, 2006. Chichester, UK: John Wiley & Sons, Ltd. Massage for mechanical neck disorders Haraldsson BG, Gross AR, Goldsmith CH, Myers CD, Ezzo JM, Morien A, Peloso P, Cervical Overview Group; Back Group In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd. Opioids for chronic low back pain Deshpande AA, Atlas S, Furlan AD, Mailis-Gagnon A, Peloso PM, Turk D; Back Group In: The Cochrane Library, Issue 4, 2004. Chichester, UK: John Wiley & Sons, Ltd. Patient education for low back pain Engers A, Jellema P, Wensing M, van Tulder; Back Group In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software Traction for low back pain with or without radiating symptoms van Tulder MW, Blomberg SEI, de Vet HCW, van der Heijden GJMG, Bronfort G, Bouter LM; Back Group In: The Cochrane Library, Issue 4, 2001. Oxford: Update Software Worksite intervention for neck and back disorders in workers. Aas RW , Holte KA , Moller A; Back Group In: The Cochrane Library, Issue 4, 2005. Chichester, UK: John Wiley & Sons, Ltd. BRAIN and SPINAL CORD TUMORS Antepileptic drugs for preventing seizures in people with brain tumors Tremont-Lukats IW, Armstrong T, Giglio P, Gilbert MR; Epilepsy Group In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software Hyperbaric oxygenation for tumour sensitisation to radiotherapy Bennett M, Feldmeier J, Smee R, Milross C; Gynaecological Cancer Group In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd. Intra-arterial chemotherapy for high grade glioma Marchioni E, Riva M, Torri V, Ceroni M, Imbesi F, Candelise L; Gynaecological Cancer Group In: The Cochrane Library, Issue 4, 2001. Oxford: Update Software Loco-regional versus standard chemotherapy for high grade gliomas Riva M, Brioschi A, Candelise L, Marchioni E; Gynaecological Cancer Group In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd. Stereotactic radiosurgery for acoustic neuroma Howard K, Ghersi D, Stockler M, Vonau M; Ear, Nose and Throat Disorders Group In: The Cochrane Library, Issue 3, 2002.Oxford: Update Software BRAIN and SPINAL INJURIES Bicycle helmet legislation for the prevention of head injuries Macpherson A, Spinks A; Injuries Group In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd. Bicycle skills training for preventing bicycle-related injuries in children and young people Macarthur C, Kmet L; Injuries Group In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd. CDP-choline for acute traumatic brain injury Chinnock P , Pokkunuri V; Injuries Group In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd. Fitness training for cardiorespiratory conditioning after traumatic brain injury Hassett LM , Moseley AM , Tate R , Harmer AR; Injuries Group In: The Cochrane Library, Issue 3, 2006. Chichester, UK: John Wiley & Sons, Ltd. Increasing motorcycle and rider conspicuity for preventing death and injury in motorcyclists Ivers R, Wells S, Blows S, Liu BC, Stevenson MS, Sing KL, Norton R; Injuries Group In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd. Intensive care sedation and analgesia for head-injury patients Arango MF, Mejia-Mantilla JH, Taneja R; Injuries Group In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd. Interventions in the alcohol server setting for preventing injuries Ker K, Chinnock P; Drugs and Alcohol Group In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley & Sons, Ltd. Interventions in the clinical setting for preventing unintentional injuries among children and teenagers aged 0-19 years Di Giuseppi C, Roberts I; Injuries Group In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software The editorial group responsible for this previously published document have withdrawn it from publication. Magnesium for acute traumatic brain injury Arango MF , Mejia Mantilla JH; Injuries Group In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd. Motorcycle helmet legislation for preventing injuries in motorcyclists Ivers RQ, Blows S, Liu BC, Lo SK, Norton R, Stevenson MS, Zhang J; Injuries Group In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd. Motorcycle rider training for preventing road traffic crashes Ivers RQ, Kardamanidis K, Lo SK, Blows S, Zhang J, Stevenson MS; Injuries Group In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd. Ref ID Psychological treatment for anxiety in people with traumatic brain injury Soo C, Tate R ; Injuries Group In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd. Ref ID: Spinal fixation surgery for acute traumatic spinal cord injury Bagnall AM, Jones L, Duffy S, Riemsma RP; Injuries Group In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd. Surgery for traumatic optic neuropathy Man PYW, Griffiths PG; Eyes and Vision Group In: The Cochrane Library, Issue 4, 2004. Chichester, UK: John Wiley & Sons, Ltd. Street lighting for preventing road traffic injuries Beyer FR, Pond P, Ker K, Roberts I; Injuries Group In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd. Ref ID: Vocational rehabilitation for acquired brain injury in adults Nair A, Turner Stokes L , Tyerman A; Injuries Group In: The Cochrane Library, Issue 2, 2006. Chichester, UK: John Wiley & Sons, Ltd. CEREBROVASCULAR DISEASE – ACUTE TREATMENT Acupuncture for dysphagia in acute stroke Xie Y , Wang L , Zhao J , Wu T; Stroke Group In: The Cochrane Library, Issue3, 2006. Chichester, UK: John Wiley & Sons, Ltd. Chuanxiong-type preparation for acute ischemic stroke Jia M , Xie L , Liu G , Wu T; Stroke Group In: The Cochrane Library, Issue 1, 2006. Chichester, UK: John Wiley & Sons, Ltd.
Load more

Recommended publications
  • Naftidrofuryl-Induced Acute Hepatic Necrosis
    Postgraduate Medical Journal (1986) 62, 309-3 10 Postgrad Med J: first published as 10.1136/pgmj.62.726.309 on 1 April 1986. Downloaded from Naftidrofuryl-induced acute hepatic necrosis J.S. de Caestecker and R.C. Heading Department ofMedicine, Royal Infirmary, Edinburgh EH3 9YW, UK. Summary: Acute hepatic necrosis is described in a 60 year old woman treated with naftidrofuryl for 5 months. Introduction Naftidrofuryl oxalate (Praxilene, Lipha) is a were demonstrated within the gallbladder. Liver vasodilator advocated for cerebral and peripheral biopsy showed extensive centrilobular necrosis with vascular disease. There have been no previous reports porto-central bridging (Figure 1). Serological tests for of hepatic damage due to this drug. We now wish to hepatitis A, hepatitis B, toxoplasma, cytomegalovirus, report a case in which severe hepatitis was related to its herpes simplex, coxiella, mycoplasma, brucella and use. leptospira were negative. Antibody to Epstein-Barr virus (IgG type) indicated past infection. Antimito- chondrial and anti-smooth muscle antibodies were Case history absent. All medication was discontinued on admission and A 60 year old woman with a history ofischaemic heart the patient made a good recovery. Four months later, disease presented with 5 months of nausea and one her bilirubin was 23 gmol/l, ALT 57 units/l, alkaline copyright. month of anorexia. She had noticed increasing jaun- phosphatase 178 units/l, gamma glutamyl transferase dice, dark urine and pale stools for 10 days. She had 112 units/l and albumin 37 g/l, and one year later her not been in contact with viral hepatitis and had not liver function tests were normal.
    [Show full text]
  • Quality Issues in Caring for Older People
    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
    [Show full text]
  • Application of Prioritization Approaches to Optimize Environmental Monitoring and Testing of Pharmaceuticals
    This is a repository copy of Application of prioritization approaches to optimize environmental monitoring and testing of pharmaceuticals. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/130449/ Article: Burns, Emily E orcid.org/0000-0003-4236-6409, Carter, Laura J, Snape, Jason R. et al. (2 more authors) (2018) Application of prioritization approaches to optimize environmental monitoring and testing of pharmaceuticals. Journal of Toxicology and Environmental Health, Part B: Critical Reviews. pp. 115-141. ISSN 1521-6950 https://doi.org/10.1080/10937404.2018.1465873 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Application of prioritization approaches to optimize environmental monitoring and testing of pharmaceuticals Emily E. Burns,† Laura J. Cater,‡ Jason Snape,§ Jane Thomas-Oates,† Alistair B.A. Boxall*‡ †Chemistry Department, University of York, Heslington, YO10 5DD, United Kingdom ‡Environment Department, University of York, Heslington, YO10 5DD, United Kingdom §AstraZeneca UK, Global Safety, Health and Environment, Macclesfield, SK10 4TG, United Kingdom *Address correspondence to [email protected] Emily E.
    [Show full text]
  • From Tinnitus to Acute Hepatitis: Drug-Induced Injury Caused by Use
    Clinics and Research in Hepatology and Gastroenterology (2019) 43, e93—e94 Available online at ScienceDirect www.sciencedirect.com LETTER TO THE EDITOR Liver enzymes were normal one year before when a blood From tinnitus to acute hepatitis: test was performed by the Occupational Medicine service. Drug-induced injury caused by use of Laboratory examination revealed cytolysis with a pre- naftidrofuryl for one year dominantly high alanine aminotransferase level associated with icteric cholestasis (Table 1). Blood tests for the most common causes, including hep- KEYWORDS atitis A, B, C and E, Epstein Barr virus, cytomegalovirus, Naftidrofuryl; autoimmune hepatitis and Wilson’s disease were negative. Acute hepatitis; An abdominal ultrasound was normal. Cholangio magnetic Drug-induced liver injury resonance imaging showed no cholelithiasis. A liver biopsy showed lesions consistent with drug- induced involvement, with many eosinophilic cells. The Naftidrofuryl is a vasodilator marketed in Europe for the other abnormalities included an inflammatory infiltrate in treatment of intermittent claudication in chronic arteriopa- the portal spaces attacking the border blade and lesions of thy, but is also used for the treatment of tinnitus. cholangitis (Fig. 1). We report a case of acute cytolytic hepatitis induced by One month after stopping naftidrofuryl, cytolysis naftidrofuryl. regressed and asthenia decreased (Table 1). Due to the A 61-year-old woman was seen in consultation for strong likelihood of drug toxicity we filed a statement with elevated liver enzymes in a blood sample performed pharmacovigilance. for asthenia. Her medical history included hepatitis A, The diagnosis of drug-induced liver injury relies on clin- endometriosis and appendectomy. ical and chronological criteria [1].
    [Show full text]
  • Pilot Experiments on the Actions of Drugs Injectedinto
    Br. J. Pharmac. (1986), 87, 495-500 Pilot experiments on the actions ofdrugs injected into the human corpus cavernosum penis G.S. Brindley Department ofPhysiology, Institute of Psychiatry De Crespigny Park, London SE5 8AF 1 Seven drugs that are known to relax smooth muscle (phenoxybenzamine, phentolamine, thymoxamine, imipramine, verapamil, papaverine, naftidrofuryl) caused erection when injected intracavernosally. 2 Salbutamol, hydralazine, lignocaine and bupivacaine caused tumidity but not erection. 3 Metaraminol and guanethidine caused shrinkage followed by tumidity. 4 Neostigmine, atropine, propranolol and idazoxan had no effect in the doses tried. 5 It is argued that the seven drugs that cause erection do so by relaxing vascular and trabecular smooth muscle within the cavernosal space, and that the two that cause shrinkage ofthe penis do so by constricting vascular and trabecular smooth muscle within the cavernosal space. 6 It is argued that muscarinic and P-adrenergic transmission play no important part in erectile mechanisms within the corpora cavernosa. 7 Papaverine, phenoxybenzamine and metaraminol, given intracavernosally, are already used therapeutically. Uses are suggested for thymoxamine, phentolamine, verapamil and guanethidine. Introduction Papaverine (Virag, 1982) and phenoxybenzamine and the left corpus cavernosum was squeezed in the same phentolamine (Brindley, 1983a; 1983b) cause erection way; then the penis was firmly pinched transversely at when given by intracavernosal injection. least six different places along it length in succession. Metaraminol, given by the same route, shrinks the These three actions were then repeated. penis (Brindley, 1984a). These drugs are now in The drugs were injected in a volume of 2 ml or less, therapeutic use (Virag, 1982; Virag et al., 1984; except for phenoxybenzamine, hydralazine and naf- Brindley, 1983b; 1984a,b; 1986; Zorgniotti & Lefleur, tidrofuryl, which were diluted with 10 ml of 0.9% 1985).
    [Show full text]
  • Ergot Derivatives Art. 31
    27 September 2013 EMA/750632/2013 Assessment report Ergot derivatives containing medicinal products International Non-proprietary Name: nicergoline Procedure number: EMEA/H/A-31/1325 Referral under Article 31 of Directive 2001/83/EC Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical efficacy .................................................................................................... 4 2.2.1. Results ............................................................................................................. 4 2.2.2. Discussion ........................................................................................................ 9 2.3. Clinical safety ...................................................................................................
    [Show full text]
  • Interactions with HBV Treatment
    www.hep-druginteractions.org Interactions with HBV Treatment Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 1 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF. ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Anaesthetics & Muscle Relaxants Antibacterials (continued) Bupivacaine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cloxacillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cisatracurium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dapsone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoflurane ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Delamanid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ketamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ertapenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nitrous oxide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Erythromycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Propofol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ethambutol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Thiopental ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Flucloxacillin ◆ ◆ ◆ ◆ ◆ ◆ Tizanidine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Gentamicin ◆ ◆ ◆ ◆ ◆ ◆ Analgesics Imipenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aceclofenac ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoniazid ◆ ◆ ◆ ◆ ◆ ◆ Alfentanil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Levofloxacin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aspirin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Linezolid ◆ ◆ ◆ ◆ ◆ ◆ Buprenorphine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lymecycline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Celecoxib ◆ ◆ ◆ ◆ ◆ ◆ ◆ Meropenem ◆ ◆ ◆ ◆ ◆ ◆ Codeine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ for distribution. for Methenamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dexketoprofen ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Metronidazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dextropropoxyphene ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Moxifloxacin ◆ ◆ ◆
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Use of Phentolamine for the Manufacture of a Medicament for the Treatment of Erectile Dysfunction
    Patentamt Europaisches |||| ||| 1 1|| ||| ||| || || || || || || || || || (19) J European Patent Office Office europeen des brevets (11) EP 0 962 225 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication:ation: (51 ) |nt. CI.6: A61 K 31 /41 5 08.12.1999 Bulletin 1999/49 (21) Application number: 99114470.0 (22) Date of filing: 26.04.1996 (84) Designated Contracting States: (72) Inventor: Lowrey, Fred AT BE CH DE DK ES Fl FR GB GR IE IT LI LU MC Lincoln, NE 6851 2 (US) NL PT SE (74) Representative: (30) Priority: 28.04.1995 US 431145 Walton, Sean Malcolm et al MEWBURN ELLIS, (62) Document number(s) of the earlier application(s) in York House, accordance with Art. 76 EPC: 23 Kingsway 9691 31 74.7 / 0 767 660 London WC2B 6HP (GB) (71) Applicant: ZONAGEN, INC. Remarks: The Woodlands, TX 77380 (US) This application was filed on 23 - 07 - 1 999 as a divisional application to the application mentioned under INID code 62. (54) Use of phentolamine for the manufacture of a medicament for the treatment of erectile dysfunction (57) The invention is directed to improved methods for modulating the human sexual response by adminis- tering an oral administered formulation of a vasodilator agent to the blood circulation thereby modulating the sexual response on demand. CM < CM CM CM CO <7> O Q_ LU Printed by Xerox (UK) Business Services 2.16.7/3.6 EP 0 962 225 A2 Description FIELD OF THE INVENTION 5 [0001] The application is directed to improved formulations for the administration of vasodilator agents to the blood circulation of a human in order to modulate the human sexual response on demand.
    [Show full text]
  • Neemmc Guidelines for Tablet Crushing and Administration Via Enteral Feeding Tubes
    NEEMMC GUIDELINES FOR TABLET CRUSHING AND ADMINISTRATION VIA ENTERAL FEEDING TUBES KEY TO DRUG ADMINISTRATION GUIDELINES Please follow the guidelines in order, as shown in the chart (i.e. number 1 is the first choice of which form to administer the drug in). A Tablet will disperse in 1-2 minutes. B Tablet will disperse in greater than 2 minutes. C Liquid preparation available. D Dilute reconstituted injection with 30-60ml of water before administering. E Oral solution/suspension can be prepared by local pharmacy or Non Sterile Preparative Services (PSU at Colchester General Hospital). Note: It is an unlicensed use to crush tablets, open capsules and make extemporaneous suspensions. However, using tablets within these guidelines is covered by the Trust for legal/vicarious liability. For more information on the administration via different tubes, please contact Medicines Information on ext. 2161. Drug Key code Information ACETAZOLAMIDE 1. A* * Diamox SR capsules can be opened and 2. D the contents flushed down the enteral tube 3. E ACICLOVIR 1. C * Dispersible tablets available 2. A* ALFACALCIDOL C* * Drops available. Sensitive to light ALFUZOSIN A Beware of sudden hypotensive effect if giving crushed tablets. Monitor BP and ensure patient is lying down prior to administering the dose. Do not crush slow release preparations. ALLOPURINOL 1. B 2. E ALVERINE Content of capsules is very bitter, and might numb the tongue and throat. AMILORIDE 1. B 2. C* * Liquid available. AMINOPHYLLINE Convert to theophylline liquid equivalent. Do not crush SR preparations. AMIODARONE B AMITRIPTYLINE 1. C 2. B AMLODIPINE A A Tablet will disperse in 1-2 minutes.
    [Show full text]
  • Cardiovascular System
    Greater Manchester Joint Formulary Chapter 2. Cardiovascular System Contents 2.1 Positive inotropic drugs 2.2 Diuretics 2.3 Anti-arrhythmic drugs 2.4 Beta-adrenoceptor blocking drugs 2.5 Hypertension and heart failure 2.6 Nitrates, calcium-channel blockers and other antianginal drugs 2.7 Not listed 2.8 Anticoagulants and protamine 2.9 Antiplatelet drugs 2.10 Stable angina, acute coronary syndromes and fibrinolysis 2.11 Anti-fibrinolytic drugs and haemostatics 2.12 Lipid-regulating drugs Key Red drug see GMMMG RAG list Click on the symbols to access this list Amber drug see GMMMG RAG list Click on the symbols to access this list Green drug see GMMMG RAG list Click on the symbols to access this list If a medicine is unlicensed this should be highlighted in the template as follows Drug name Not Recommended OTC Over the Counter In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see GM commissioning statement. Order of Drug Choice Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order. Return to contents page V6.3 Chapter 2 – page 1 of 18 Greater Manchester Joint Formulary Additional notes for chapter 2 Monitoring of renal function and electrolytes is required for many of drugs covered in this chapter, especially in patients who are on multiple drug therapy. Ensure appropriate monitoring for following drugs or groups of drugs: Digoxin – monitor for signs of toxicity especially in elderly. NB hyperkalaemia can predispose to digitalis toxicity.
    [Show full text]